The feasibility of procalcitonin and CPIS score to reduce inappropriate antibiotics use among severe-critically ill COVID-19 pneumonia patients: A pilot study
3
Issued Date
2022-05-01
Resource Type
ISSN
01966553
eISSN
15273296
Scopus ID
2-s2.0-85127355725
Pubmed ID
35158008
Journal Title
American Journal of Infection Control
Volume
50
Issue
5
Start Page
581
End Page
584
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Infection Control Vol.50 No.5 (2022) , 581-584
Suggested Citation
Sathitakorn O., Jantarathaneewat K., Weber D.J., Warren D.K., Nanthapisal S., Rutjanawech S., Apisarnthanarak P., Apisarnthanarak A. The feasibility of procalcitonin and CPIS score to reduce inappropriate antibiotics use among severe-critically ill COVID-19 pneumonia patients: A pilot study. American Journal of Infection Control Vol.50 No.5 (2022) , 581-584. 584. doi:10.1016/j.ajic.2022.01.030 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85931
Title
The feasibility of procalcitonin and CPIS score to reduce inappropriate antibiotics use among severe-critically ill COVID-19 pneumonia patients: A pilot study
Other Contributor(s)
Abstract
Antibiotics have been extensively used in COVID-19 patients without a clear indication. We conducted a study to evaluate the feasibility of procalcitonin along with the “Clinical Pulmonary for Infection Score” (CPIS) as a strategy to reduce inappropriate antibiotic use. Using procalcitonin and CPIS score (PCT-CPIS) successfully reduced inappropriate antibiotics use among severe-critically ill COVID-19 pneumonia patients (45% vs 100%; P <.01). Compared to “non PCT-CPIS” group, “PCT-CPIS” group was associated with a reduction in the incidence of multidrug-resistant organisms and invasive fungal infections (18.3% vs 36.7%; P =.03), shorter antibiotic duration (2 days vs 7 days; P <.01) and length of hospital stay (10 days vs 16 days; P <.01).